Our Team
At the heart of our innovations and success lies a team of passionate, dedicated, and visionary individuals. Hailing from diverse backgrounds, each member brings a unique perspective, expertise, and drive to our collective table.
But what truly binds us together is an unwavering commitment to improving global health. From our top-tier scientists unlocking the mysteries of cellular behavior to our dynamic strategists carving out new market paths, our team is our most treasured asset. Their collective dedication and perseverance are what propels us forward, ensuring that we continue to break barriers and redefine standards in the biotech industry.
Company
Firm name | Eighty-Eighty Therapeutics Co., Ltd. |
Representative | Founder and CEO Hiroshi Yamamoto |
Establishment | 2019/09 (as H&L consulting service), 2023/06 (convert to Eighty-Eighty TA) |
HQ | Shibuya, Tokyo |
Business | Biotech (Drug Discovery, R&D, Regulatory, Commercialization) Healthcare Business Consulting New Company Creation (NewCo, In-Licensed Product for R&D, Commercialization) |
Stakeholders | Founder and others |
Partner | Researchtransfer http://www.researchtransfer.de/ Tsukishima Kachidoki law firm |
Earnings | 45M JPY + SO (2023/08) |